M. Kulyk & Associates’s DexCom DXCM Stock Holding History

M. Kulyk & Associates’s Portfolio DXCM Stock Details DXCM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-1,575	Closed	-$218K	–	114
2024 Q1	$218K	Buy	+1,575	New	+$198K	0.05%	102

Other funds holding DXCM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

M. Kulyk & Associates's DXCM Position: Q2 2024 in Review

M. Kulyk & Associates sold out of DexCom (DXCM) in Q2 2024, closing a stake of 1,575 shares — an estimated $218K sold.

M. Kulyk & Associates first reported a position in DXCM in Q1 2024 and held it in 1 quarter. The position peaked at $218K in Q1 2024. 999 funds tracked by Wall St. Rank hold DXCM as of Q2 2024.

M. Kulyk & Associates reported no remaining DexCom position as of Q2 2024 after selling out during the quarter.
M. Kulyk & Associates sold 1,575 DexCom shares in Q2 2024, an estimated $218K.
M. Kulyk & Associates first reported a position in DexCom in Q1 2024 and held it in 1 quarter.
M. Kulyk & Associates's DexCom position peaked at $218K in Q1 2024.
999 funds tracked by Wall St. Rank held DexCom as of Q2 2024.

Based on M. Kulyk & Associates's 13F filing for Q2 2024, filed 5 Aug 2024.